98%
921
2 minutes
20
This study aimed to identify the prevalence of substance use before and during COVID-19; and examined its association with depression and social factors among 437 residents from the neighborhood of Harlem in Northern Manhattan, New York City. Over a third of respondents reported using any substance before COVID-19, and initiating/increasing substance use during COVID-19. The most common substances used before COVID-19 and initiated/increased during COVID-19 were smoking (20.8% vs. 18.3%), marijuana (18.8% vs. 15.3%), and vaping (14.2% and 11.4%). The percentages of any hard drug use were 7.3% and 3.4%, respectively. After adjustment, residents with mild (Prevalence Ratio [PR] = 2.86, 95% CI 1.65, 4.92) and moderate (PR = 3.21, 95% CI 1.86, 5.56) symptoms of depression, and housing insecurity (PR = 1.47, 95% CI 1.12, 1.91) had at least a 47% greater probability of initiating and/or increasing substance use. Conversely, respondents with employment insecurity (PR = 0.71, 95% CI 0.57, 0.88) were 29% less likely to report such patterns. No association was found between substance use initiation and/or increase and food insecurity. High prevalence of substance use during COVID-19 may lead residents to turn to substance use as a coping mechanism for psychosocial stressors. Thus, it is essential to provide accessible and culturally sensitive mental health and substance use services.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591977 | PMC |
http://dx.doi.org/10.1007/s10900-023-01253-1 | DOI Listing |
Eur Arch Psychiatry Clin Neurosci
September 2025
School of Public Health, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Concerns over the mental health among young people have been increasing recently. We aimed to estimate the burdens of mental disorders, substance use disorders (SUDs), and self-harm at global, regional and national levels among adolescents and young adults aged 10-24 years from 1990 to 2021. Incidence, prevalence, and disability-adjusted life years (DALYs) of mental disorders, SUDs, and self-harm among young people were examined by age, sex, region, and country/territory.
View Article and Find Full Text PDFJ Clin Exp Neuropsychol
September 2025
Department of Psychology, University of British Columbia, Vancouver, Canada.
Background: Metamemory is the awareness of and ability to evaluate one's own cognitive abilities. This study examined impaired metamemory as a possible mechanism contributing to persistent cognitive symptoms after COVID-19.
Methods: Individuals with previous COVID-19 illness were recruited.
J Ethn Subst Abuse
September 2025
Department of Psychology and Center on Alcohol, Substance use, And Addiction (CASAA), University of New Mexico, Albuquerque, NM, USA.
Background: American Indian and Alaska Native (AI/AN) communities experienced a disproportionate increase in opioid-related fatal and non-fatal poisonings during the COVID-19 pandemic. Access to treatment, such as medications for opioid use disorder (MOUD), became even more critical, although research among this population is limited. We completed qualitative interviews with substance use disorder (SUD) treatment providers (i.
View Article and Find Full Text PDFAutoimmunity
December 2025
Medicinal Genomics, Beverly, MA, USA.
For some of the COVID-19 vaccines, the drug substances released to market were manufactured differently than those used in clinical trials. Manufacturing nucleoside-modified mRNA (modRNA) for commercial COVID-19 vaccines relies on RNA polymerase transcription of a plasmid DNA template. Previous studies identified high levels of plasmid DNA in vials of modRNA vaccines, suggesting that the removal of residual DNA template is problematic.
View Article and Find Full Text PDFMedComm (2020)
September 2025
The emergence of novel and highly transmissible coronavirus (CoVs) highlights the urgent need for broad-spectrum antiviral agents. In our pursuit of effective treatments for coronavirus, we identified tetrandrine, the traditional Chinese medicine, as a pan-coronavirus inhibitor, exhibiting efficacy against HCoV-229E, HCoV-OC43, SARS-CoV-2, and its major variants of concern (VOCs), including alpha, beta, and omicron. Mechanistic investigations revealed that tetrandrine primarily targets the viral entry stage by binding to the Spike protein, disrupting its interaction with the host protease transmembrane serine protease 2 (TMPRSS2), and promoting Spike protein degradation, ultimately blocking the membrane fusion.
View Article and Find Full Text PDF